Squarepoint’s IGC Pharma IGC Stock Holding History

Squarepoint’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-140,510	Closed	-$40K	–	4742
2025 Q1	$40K	Buy	140,510 +14,544	+12%	+$4.59K	﹤0.01%	4378
2024 Q4	$42.3K	Buy	+125,966	New	+$47.1K	﹤0.01%	4870
2021 Q3	–	Sell	-12,182	Closed	-$20K	–	3144
2021 Q2	$20K	Buy	+12,182	New	+$18.6K	﹤0.01%	3148

Other funds holding IGC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Dearborn Partners Chicago, Illinois $1.77B AUM 9.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Squarepoint's IGC Position: Q2 2025 in Review

Squarepoint sold out of IGC Pharma (IGC) in Q2 2025, closing a stake of 140,510 shares — an estimated $40K sold.

Squarepoint first reported a position in IGC in Q2 2021 and held it in 3 quarters. The position peaked at $42.3K in Q4 2024. 28 funds tracked by Wall St. Rank hold IGC as of Q2 2025.

Squarepoint reported no remaining IGC Pharma position as of Q2 2025 after selling out during the quarter.
Squarepoint sold 140,510 IGC Pharma shares in Q2 2025, an estimated $40K.
Squarepoint first reported a position in IGC Pharma in Q2 2021 and held it in 3 quarters.
Squarepoint's IGC Pharma position peaked at $42.3K in Q4 2024.
28 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.